Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines

European Journal of Cancer

Volumn 46, Issue 9, 2010, Pages 1514-1519

  Sasada, Tetsuro ^a,b   Komatsu, Nobukazu ^a   Suekane, Shigetaka ^a,b   Yamada, Akira ^a   Noguchi, Masanori ^a   Itoh, Kyogo ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Cancer vaccine; Immune response; Personalisation; Randomised clinical trial

Indexed keywords

BIOLOGICAL MARKER; CANCER VACCINE; CANVAXIN; FAVID; FAVID VACCINE; GM2 KLH21; GM2 KLH21 VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IMMUNOMODULATING AGENT; MELACINE; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; MYVAX; MYVAX VACCINE; PANVAC VF; PANVAC VF VACCINE; PROVENGE; THERATOPE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VITESPEN; WART VIRUS VACCINE; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER IMMUNIZATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG APPROVAL; DRUG TREATMENT FAILURE; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOLOGICAL MONITORING; KIDNEY CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; VERRUCA VULGARIS; IMMUNOLOGY; METABOLISM; NEOPLASMS; PHARMACEUTICS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TECHNOLOGY, PHARMACEUTICAL; TUMOR MARKERS, BIOLOGICAL;

EID: 77952582258     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.03.013     Document Type: Article

References (37)

1. van der Bruggen P., Traversari C., Chomez P., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254 5038 (1991) 1643-1647
2. Schlom J., Gulley J.L., and Arlen P.M. Paradigm shifts in cancer vaccine therapy. Exp Biol Med 233 (2008) 522-534
3. Cheever M.A., Allison J.P., Ferris A.S., et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15 (2009) 5323-5337
4. Purcell A.W., McCluskey J., and Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 6 (2007) 404-414
5. Itoh K., Yamada A., Mine T., and Noguchi M. Recent advances in cancer vaccines: an overview. Jpn J Clin Oncol 39 (2009) 73-80
6. Finke L.H., Wentworth K., Blumenstein B., et al. Lessons from randomized phase III studies with active cancer immunotherapies - outcomes from the 2006 meeting of the cancer vaccine consortium (CVC). Vaccine 25 (2007) B97-B109
7. Goldman B., and DeFrancesco L. The cancer vaccine roller coaster. Nat Biotechnol 27 (2009) 129-139
8. Eggermont A.M.M.M. Therapeutic vaccines in solid tumours: can they be harmful?. Eur J Cancer 45 (2009) 2087-2090
9. US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for Industry; Clinical Considerations for Therapeutic Cancer Vaccines, draft guidance; 2009 [September].
10. Dunne E.F., Datta S.D., and Markowitz L.E. A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US. Cancer 113 (2008) 2995-3003
11. Lassi K, Dawson NA. Update on castrate-resistant prostate cancer: 2010. Curr Opin Oncol, in press.
12. Bendandi M. Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures. Nat Rev Cancer 9 (2009) 675-681
13. Kenter G.G., Welters M.J.P., Valentijn A., et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 361 (2009) 1838-1847
14. Barve M., Bender J., Senzer N., et al. Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol 26 (2008) 4418-4425
15. Yajima N., Yamanaka R., Mine T., et al. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res 11 (2005) 5900-5911
16. Noguchi M., Mine T., Yamada A., et al. Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: an analysis of prognostic factors in the treatment. Oncol Res 16 (2007) 341-349
17. Noguchi M, Kakuma T, Uemura T, et al. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother, in press.
18. Kantoff P.W., Schuetz T.J., Blumenstein B.A., et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 28 (2010) 1099-1105
19. Cheever M.A. Twelve immunotherapy drugs that could cure cancers. Immunol Rev 222 (2008) 357-368
20. Eggermont A.M. Immunostimulation versus immunosuppression after multiple vaccinations: the woes of therapeutic vaccine development. Clin Cancer Res 15 (2009) 6745-6747
21. Whiteside T.L. Immune monitoring of clinical trials with biotherapies. Adv Clin Chem 45 (2008) 75-97
22. Britten C.M., Gouttefangeas C., Welters M.J.P., et al. The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8(+) T lymphocytes by structural and functional assays. Cancer Immunol Immunother 57 (2008) 289-302
23. Janetzki S., Britten C.M., Kalos M., et al. "MIATA" - minimal information about T cell assays. Immunity 31 (2009) 527-528
24. Hida N., Maeda Y., Katagiri K., et al. A simple culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulation. Cancer Immunol Immunother 51 (2002) 219-228
25. Komatsu N., Shichijo S., Nakagawa M., and Itoh K. New multiplexed flow cytometric assay to measure anti-peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization. Scand J Clin Lab Invest 64 (2004) 535-545
26. Hattori T., Mine T., Komatsu N., et al. Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients. Cancer Immunol Immunother 58 (2009) 1845-1854
27. Valmori D., Souleimanian N.E., Tosello V., et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci USA 104 (2007) 8947-8952
28. Mochizuki K., Sato Y., Tsuda N., et al. Immunological evaluation of vaccination with pre-designated peptides frequently selected as vaccine candidates in an individualized peptide vaccination regimen. Int J Oncol 25 (2004) 121-131
29. Chen W., and McCluskey J. Immunodominance and immunodomination: critical factors in developing effective CD8(+) T-cell-based cancer vaccines. Adv Cancer Res 95 (2006) 203-247
30. Hoos A., Parmiani G., Hege K., et al. A clinical development paradigm for cancer vaccines and related biologics. J Immunother 30 (2007) 1-15
31. Noguchi M., Yao A., Harada M., et al. Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer. Prostate 67 (2007) 933-942
32. Curiel T.J., Coukos G., Zou L., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10 (2004) 942-949
33. Pages F., Berger A., Camus M., et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353 (2005) 2654-2666
34. Whiteside T.L. The tumor microenvironment and its role in promoting tumor growth. Oncogene 27 (2008) 5904-5912
35. Hodi F.S., Butler M., Oble D.A., et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 105 (2008) 3005-3010
36. Homma S., Komohara Y., Harada M., et al. Differential levels of human leukocyte antigen-class I, multidrug-resistance 1 and androgen receptor expressions in untreated prostate cancer cells: the robustness of prostate cancer. Oncol Rep 18 (2007) 343-346
37. Zitvogel L., Apetoh L., Ghiringhelli F., and Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8 (2008) 59-73